You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Novel Approach to Immunotherapy.
SBC: CADRE BIOSCIENCE, LLC Topic: NCIPROJECT SUMMARY/ABSTRACT. This phase 1 SBIR project proposes development of a new type of drug to improve the treatment of cancer. This new approach offers potential in many forms of the disease, including breast cancer, which is second only to cancer of the lung in terms of mortality. In particular, triple negative breast cancer (TNBC) is very challenging to treat as there are fewer therapeutic o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
SBC: NEUTHERAPEUTICS, LLC Topic: NIAProject Summary/Abstract Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. Current thinking in the field embraces the complexity of AD pathophysiology, which has enabled a more dive ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
SBC: FIMBRION THERAPEUTICS INC Topic: RProject Summary/Abstract Tuberculosis (TB), caused by infection with the bacterium Mycobacterium tuberculosis (Mtb), is a leading cause of mortality due to infection, globally. In 2020, 10 million people were newly diagnosed with TB and 1.5 million people died from the disease. As efforts to treat TB expand, the prevalence of infections caused by drug-resistant Mtb strains (DR-TB) that are resista ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Previvors Recharge: A Resilience Program for Cancer Previvors
SBC: Pro-Change Behavior Systems, Inc. Topic: 102It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Beat Extreme: An Interactive, Tailored Text Messaging Program Combining Extreme Weather Alerts with Hyper-localized Resources and Actionable Insights for Addressing Climate Change
SBC: Pro-Change Behavior Systems, Inc. Topic: RSummary Climate change is an urgent public health threat, and climate-related health risks disproportionately impact vulnerable populations. Public health agencies have underscored the need to develop scalable and innovative health-equity centered, multi-level interventions that offer tools and resources to 1) raise awareness of the inextricable link between climate change and health and 2) suppor ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Islet dosing and loading density in injection molded macroencapsulation devices
SBC: IMMUNOSHIELD THERAPEUTICS INC. Topic: 200PROJECT SUMMARY/ABSTRACT: Clinical islet transplantation is a promising alternative therapy for the treatment of type 1 diabetes, with the potential to reduce or eliminate secondary complications and adverse events. The potent immune response to islets remains the greatest challenge to long-term engraftment and function, which necessitates large numbers of islets and typically multiple pancreatic ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Accelerated absorption of insulin via a subcutaneously implanted, vascularized micro-chamber
SBC: PROCYON TECHNOLOGIES LLC Topic: 200Project Summary In Type I diabetic (T1D) patients, insulin is injected into the subcutaneous (SC) tissue, by needle or a pump and SC cannula. A bolus of insulin SC reaches its peak in about one hour or more. This slow absorption is in dramatic contrast to the secretion of insulin into the blood by the normal human pancreas, a process measured in seconds. Consequently, patients with T1D often strug ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Plans4Care: Personalized Dementia Care On-Demand
SBC: Plans4Care INC Topic: RPROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Platform to Identify Antifungal Compounds with Novel Action Mechanisms
SBC: INTACT GENOMICS INC Topic: R43Project Summary There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. Antifungal compound discovery has been forgotten or neglected (see a review publication 2021 at Research Strategy). One of the best possible sources for new antifungal compounds with potentially novel mechanisms of action i ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation
SBC: IMETABOLIC BIOPHARMA CORP Topic: NHLBIProject Abstract Cardiovascular Disease (CVD) is a significant threat in the United States and developing countries across the globe. Widely associated with elevated low density lipoprotein cholesterol (LDL-c), therapeutic interventions are primarily focused on reduction of LDL-c plasma levels. Despite the ability to therapeutically reach these target levels, many patients maintain high cardiovasc ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health